Emergent BioSolutions News

Emergent BioSolutions Analyst Ratings

BenzingaApr 11 09:03 ET

Analysts' Top Healthcare Picks: Emergent Biosolutions (EBS), Vera Therapeutics (VERA)

TipRanksApr 11 07:20 ET

Emergent BioSolutions Analyst Ratings

BenzingaMar 7 10:37 ET

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and Emergent Biosolutions (EBS)

TipRanksJan 11 10:20 ET

Emergent BioSolutions Analyst Ratings

BenzingaNov 20, 2023 08:27 ET

Emergent BioSolutions Analyst Ratings

BenzingaAug 29, 2023 06:38 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY), Galapagos (GLPG) and Emergent Biosolutions (EBS)

TipRanksMay 31, 2023 12:30 ET

What 4 Analyst Ratings Have To Say About Emergent BioSolutions

BenzingaMay 31, 2023 12:01 ET

Benchmark Reiterates Buy on Emergent BioSolutions, Maintains $22 Price Target

BenzingaMay 31, 2023 08:13 ET

Analysts Offer Insights on Healthcare Companies: Emergent Biosolutions (EBS) and HeartBeam (BEAT)

TipRanksMay 19, 2023 12:30 ET

Benchmark Reiterates Buy on Emergent BioSolutions, Maintains $22 Price Target

BenzingaMay 19, 2023 09:33 ET

Benchmark Upgrades Emergent BioSolutions to Buy, Announces $22 Price Target

BenzingaApr 10, 2023 06:57 ET

Analysts Offer Insights on Healthcare Companies: Emergent Biosolutions (EBS), Syndax Pharmaceuticals (SNDX) and Mersana Therapeutics (MRSN)

TipRanksMar 31, 2023 08:16 ET

Emergent BioSolutions Analyst Ratings

Benzinga Analyst RatingsNov 10, 2022 13:42 ET

'Waiting Game Continues' In Emergent BioSolutions, Analysts Cut Price Target

Benzinga Real-time NewsNov 9, 2022 13:20 ET

MannKind To Rally 57%? Here Are 5 Other Price Target Changes For Wednesday

Benzinga Real-time NewsNov 9, 2022 08:07 ET

Emergent BioSolutions Analyst Ratings

Benzinga Analyst RatingsNov 9, 2022 07:38 ET

Chardan Capital Maintains Buy on Emergent BioSolutions, Lowers Price Target to $55

Benzinga Real-time NewsNov 9, 2022 07:38 ET

Analysts Offer Insights on Healthcare Companies: Emergent Biosolutions (EBS), Inovio Pharmaceuticals (INO) and Assembly Biosciences (ASMB)

TipRanksNov 9, 2022 06:50 ET

Chardan Cuts Price Target on Emergent Biosolutions to $55 From $65 on Slower Revenue, Profitability Growth; Keeps Buy Rating

MT NewswiresNov 9, 2022 06:35 ET